Estimated Effectiveness of Prior SARS-CoV-2 BA.1 or BA.2 Infection and Booster Vaccination Against Omicron BA.5 Subvariant Infection-Reference-Cited by-同舟云学术

Estimated Effectiveness of Prior SARS-CoV-2 BA.1 or BA.2 Infection and Booster Vaccination Against Omicron BA.5 Subvariant Infection

Published:2023-03-10 Issue:3 Volume:6 Page:e232578
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Jang Eun Jung¹,Choe Young June²,Kim Ryu Kyung¹,Lee Sangwon¹,Park Seon Kyeong¹,Park Young-Joon¹

Affiliation:

1. Korea Disease Control and Prevention Agency, Cheongju, South Korea

2. Korea University Anam Hospital, Seoul, South Korea

Abstract

This case-control study estimates the effectiveness of prior SARS-CoV-2 BA.1 or BA.2 infection and booster vaccination against Omicron BA.5 subvariant infection.

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2802258/jang_2023_ld_230018_1677703639.98439.pdf

Reference6 articles.

1. Booster COVID-19 vaccination against the SARS-CoV-2 Omicron variant: a systematic review.;Du;Hum Vaccin Immunother,2022

2. mRNA vaccine effectiveness against COVID-19-related hospitalisations and deaths in older adults: a cohort study based on data linkage of national health registries in Portugal, February to August 2021.;Nunes;Euro Surveill,2021

3. Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection.;Hall;N Engl J Med,2022

4. Association of primary and booster vaccination and prior infection with SARS-CoV-2 infection and severe COVID-19 outcomes.;Lin;JAMA,2022

5. Protective effect of previous SARS-CoV-2 infection against Omicron BA.4 and BA.5 subvariants.;Altarawneh;N Engl J Med,2022

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SARS-CoV-2-specific cellular and humoral immunity after bivalent BA.4/5 COVID-19-vaccination in previously infected and non-infected individuals;Nature Communications;2024-04-09

2. Risk of subsequent SARS‐CoV‐2 infection among vaccinated employees with or without hybrid immunity acquired early in the Omicron‐predominant era of the COVID‐19 pandemic;American Journal of Industrial Medicine;2024-02-05

3. Protection of Omicron Sub-Lineage Infection Against Reinfection with Another Omicron Sub-Lineage: Systematic Review, Meta-Analysis, and Meta-Regression — Worldwide, 2022–2023;China CDC Weekly;2024

4. Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against symptomatic COVID-19 among immunocompetent individuals testing at a large US retail pharmacy;The Journal of Infectious Diseases;2023-10-31

5. Preinfection Neutralizing Antibodies, Omicron BA.5 Breakthrough Infection, and Long COVID: A Propensity Score-Matched Analysis;The Journal of Infectious Diseases;2023-09-26